Document:

================================================================================
Exhibit 10.1; Direct Response Financial Services, Inc. 2004 Stock Incentive
Plan.

                    DIRECT RESPONSE FINANCIAL SERVICES, INC.
                            2004 STOCK INCENTIVE PLAN

SECTION 1. General Purpose of the Plan; Definitions.

     The name of the plan is the DIRECT RESPONSE FINANCIAL SERVICES, Inc. 2004
Stock Incentive Plan (the "Plan"). The purpose of the Plan is to encourage and
enable officers, directors, and employees of DIRECT RESPONSE FINANCIAL SERVICES,
Inc. (the "Company") and its Subsidiaries and other persons to acquire a
proprietary interest in the Company. It is anticipated that providing such
persons with a direct stake in the Company's welfare will assure a closer
identification of their interests with those of the Company and its
shareholders, thereby stimulating their efforts on the Company's behalf and
strengthening their desire to remain with the Company.

     The following terms shall be defined as set forth below:

     "Award" or "Awards", except where referring to a particular category of
grant under the Plan, shall include Incentive Stock Options, Non-Statutory Stock
Options, Restricted Stock Awards, Unrestricted Stock Awards, Performance Share
Awards and Stock Appreciation Rights.
     "Board" means the Board of Directors of the Company.
     "Cause" means (i) any material breach by the participant of any agreement
to which the participant and the Company are both parties, and (ii) any act or
omission justifying termination of the participant's employment for cause, as
determined by the Committee.
     "Change of Control" shall have the meaning set forth in Section 15.
     "Code" means the Internal Revenue Code of 1986, as amended, and any
successor Code, and related rules, regulations and interpretations.
     "Conditioned Stock Award" means an Award granted pursuant to Section 6.
     "Committee" shall have the meaning set forth in Section 2.
     "Disability" means disability as set forth in Section 22(e)(3) of the Code.
     "Effective Date" means the date on which the Plan is approved by
stockholders as set forth in Section 17.
     "Eligible Person" shall have the meaning set forth in Section 4.
     "Fair Market Value" on any given date means the price per share of the
Stock on such date as reported by a nationally recognized stock exchange, or, if
the Stock is not listed on such an exchange, as reported by NASDAQ, or, if the
Stock is not quoted on NASDAQ, the fair market value of the Stock as determined
by the Committee.
     "Incentive Stock Option" means any Stock Option designated and qualified as
an "incentive stock option" as defined in Section 422 of the Code.
     "Non-Statutory Stock Option" means any Stock Option that is not an
Incentive Stock Option.
     "Normal Retirement" means retirement from active employment with the
Company and its Subsidiaries in accordance with the retirement policies of the
Company and its Subsidiaries then in effect.
     "Outside Director" means any director who (i) is not an employee of the
Company or of any "affiliated group," as such term is defined in Section 1504(a)
of the Code, which includes the Company (an "Affiliate"), (ii) is not a former
employee of the Company or any Affiliate who is receiving compensation for prior
services (other than benefits under a tax-qualified retirement plan) during the
Company's or any Affiliate's taxable year, (iii) has not been an officer of the

<PAGE>

Company or any Affiliate and (iv) does not receive remuneration from the Company
or any Affiliate, either directly or indirectly, in any capacity other than as a
director. "Outside Director" shall be determined in accordance with Section
162(m) of the Code and the Treasury regulations issued thereunder.
     "Option" or "Stock Option" means any option to purchase shares of Stock
granted pursuant to Section 5.
     "Performance Share Award" means an Award granted pursuant to Section 8.
     "Stock" means the Common Stock, no par value, of the Company, subject to
adjustments pursuant to Section 3.
     "Stock Appreciation Right" means an Award granted pursuant to Section 9.
     "Subsidiary" means a subsidiary as defined in Section 424 of the Code.
     "Unrestricted Stock Award" means Awards granted pursuant to Section 7.

SECTION 2. Administration of Plan; Committee Authority to Select Participants
and Determine Awards.

     (a)  Committee. The Plan shall be administered by a committee of the Board
(the "Committee") consisting of not less than two (2) Outside Directors, but the
authority and validity of any act taken or not taken by the Committee shall not
be affected if any person administering the Plan is not an "Outside Director."
The Board of Directors may act as the Committee at any time. Except as
specifically reserved to the Board under the terms of the Plan, the Committee
shall have full and final authority to operate, manage and administer the Plan
on behalf of the Company. Action by the Committee shall require the affirmative
vote of a majority of all members thereof. The Board may establish an additional
single-member committee (consisting of an executive officer) that shall have the
power and authority to grant Awards to non-executive officers and to make all
other determinations under the Plan with respect thereto.
     (b)  Powers of Committee. The Committee shall have the power and authority
to grant and modify Awards consistent with the terms of the Plan, including the
power and authority:
          (i)  to select the persons to whom Awards may from time to time be
granted;
          (ii) to determine the time or times of grant, and the extent, if any,
of Incentive Stock Options, Non-Statutory Stock Options, Restricted Stock,
Unrestricted Stock, Performance Shares and Stock Appreciation Rights, or any
combination of the foregoing, granted to any one or more participants;
          (iii) to determine the number of shares to be covered by any Award;
          (iv) to determine and modify the terms and conditions, including
restrictions, not inconsistent with the terms of the Plan, of any Award, which
terms and conditions may differ among individual Awards and participants, and to
approve the form of written instruments evidencing the Awards; provided,
however, that no such action shall adversely affect rights under any outstanding
Award without the participant's consent;
          (v)  to accelerate the exercisability or vesting of all or any portion
of any Award;
          (vi) subject to the provisions of Section 5(b), to extend the period
in which any outstanding Stock Option or Stock Appreciation Right may be
exercised;
          (vii) to determine whether, to what extent, and under what
circumstances Stock and other amounts payable with respect to an Award shall be
deferred either automatically or at the election of the participant and whether
and to what extent the Company shall pay or credit amounts equal to interest (at
rates determined by the Committee) or dividends or deemed dividends on such
deferrals; and

<PAGE>

          (viii) to adopt, alter and repeal such rules, guidelines and practices
for administration of the Plan and for its own acts and proceedings as it shall
deem advisable; to interpret the terms and provisions of the Plan and any Award
(including related written instruments); to make all determinations it deems
advisable for the administration of the Plan; to decide all disputes arising in
connection with the Plan; and to otherwise supervise the administration of the
Plan.
     All decisions and interpretations of the Committee shall be binding on all
persons, including the Company and Plan participants.

SECTION 3. Shares Issuable under the Plan; Mergers; Substitution.

     (a)  Shares Issuable. The maximum number of shares of Stock with respect to
which Awards (including Stock Appreciation Rights) may be granted under the Plan
shall be Five Hundred Thousand (500,000). For purposes of this limitation, the
shares of Stock underlying any Awards which are forfeited, cancelled, reacquired
by the Company or otherwise terminated (other than by exercise) shall be added
back to the shares of Stock with respect to which Awards may be granted under
the Plan so long as the participants to whom such Awards had been previously
granted received no benefits of ownership of the underlying shares of Stock to
which the Award related. Subject to such overall limitation, any type or types
of Award may be granted with respect to shares, including Incentive Stock
Options. Shares issued under the Plan may be authorized but unissued shares or
shares reacquired by the Company.
     (b)  Stock Dividends, Mergers, etc. In the event that after approval of the
Plan by the directors of the Company in accordance with Section 17, the Company
effects a stock dividend, stock split or similar change in capitalization
affecting the Stock, the Committee shall make appropriate adjustments in (i) the
number and kind of shares of stock or securities with respect to which Awards
may thereafter be granted (including without limitation the limitations set
forth in Section 3(a) and Section 3(b) above), (ii) the number and kind of
shares remaining subject to outstanding Awards, and (iii) the option or purchase
price in respect of such shares. In the event of any merger, consolidation,
dissolution or liquidation of the Company, the Committee in its sole discretion
may, as to any outstanding Awards, make such substitution or adjustment in the
aggregate number of shares reserved for issuance under the Plan and in the
number and purchase price (if any) of shares subject to such Awards as it may
determine and as may be permitted by the terms of such transaction, or
accelerate, amend or terminate such Awards upon such terms and conditions as it
shall provide (which, in the case of the termination of the vested portion of
any Award, shall require payment or other consideration which the Committee
deems equitable in the circumstances), subject, however, to the provisions of
Section 15.
     (c)  Substitute Awards. The Committee may grant Awards under the Plan in
substitution for stock and stock based awards held by employees of another
corporation who concurrently become employees of the Company or a Subsidiary as
the result of a merger or consolidation of the employing corporation with the
Company or a Subsidiary or the acquisition by the Company or a Subsidiary of
property or stock of the employing corporation. The Committee may direct that
the substitute awards be granted on such terms and conditions as the Committee
considers appropriate in the circumstances. Shares which may be delivered under
such substitute awards may be in addition to the maximum number of shares
provided for in Section 3(a).

<PAGE>

SECTION 4. Eligibility.

     Awards may be granted to officers, directors, and employees of and
consultants and advisers to the Company or its Subsidiaries ("Eligible
Persons").

SECTION 5. Stock Options.

     The Committee may grant to Eligible Persons options to purchase stock.
     Any Stock Option granted under the Plan shall be in such form as the
Committee may from time to time approve.
     Stock Options granted under the Plan may be either Incentive Stock Options
(subject to compliance with applicable law) or Non-Statutory Stock Options.
Unless otherwise so designated, an Option shall be a Non-Statutory Stock Option.
To the extent that any option does not qualify as an Incentive Stock Option, it
shall constitute a Non-Statutory Stock Option.
     No Incentive Stock Option shall be granted under the Plan after the tenth
anniversary of the earlier of (i) the date of adoption of the Plan by the Board,
or (ii) the date on which the Plan is ratified by the stockholders as set forth
in Section 17.
     The Committee in its discretion may determine the effective date of Stock
Options, provided, however, that grants of Incentive Stock Options shall be made
only to persons who are, on the effective date of the grant, employees of the
Company or any Subsidiary. Stock Options granted pursuant to this Section 5(a)
shall be subject to the following terms and conditions and the terms and
conditions of Section 13 and shall contain such additional terms and conditions,
not inconsistent with the terms of the Plan, as the Committee shall deem
desirable.

     (a)  Exercise Price. The exercise price per share for the Stock covered by
a Stock Option granted pursuant to this Section 5(a) shall be determined by the
Committee at the time of grant but shall be, in the case of Incentive Stock
Options, not less than one hundred percent (100%) of Fair Market Value on the
date of grant. If an employee owns or is deemed to own (by reason of the
attribution rules applicable under Section 424(d) of the Code) more than ten
percent (10%) of the combined voting power of all classes of stock of the
Company or any Subsidiary or parent corporation and an Incentive Stock Option is
granted to such employee, the option price shall be not less than one hundred
ten percent (110%) of Fair Market Value on the grant date.
     (b)  Option Term. The term of each Stock Option shall be fixed by the
Committee, but no Incentive Stock Option shall be exercisable more than ten (10)
years after the date the option is granted. If an employee owns or is deemed to
own (by reason of the attribution rules of Section 424(d) of the Code) more than
ten percent (10%) of the combined voting power of all classes of stock of the
Company or any Subsidiary or parent corporation and an Incentive Stock Option is
granted to such employee, the term of such option shall be no more than five (5)
years from the date of grant.
     (c)  Exercisability; Rights of a Shareholder. Stock Options shall become
vested and exercisable at such time or times, whether or not in installments, as
shall be determined by the Committee at or after the grant date. The Committee
may at any time accelerate the exercisability of all or any portion of any Stock
Option. An optionee shall have the rights of a shareholder only as to shares
acquired upon the exercise of a Stock Option and not as to unexercised Stock
Options.
     (d)  Method of Exercise. Stock Options may be exercised in whole or in
part, by delivering written notice of exercise to the Company, specifying the
number of shares to be purchased. Payment of the purchase price may be made by
one or more of the following methods:
          (i)  In cash or by certified or bank check or other instrument
acceptable to the Committee;

<PAGE>

          (ii) If permitted by the Committee, in its discretion, in the form of
shares of Stock that are not then subject to restrictions and that have been
owned by the optionee for a period of at least six months. Such surrendered
shares shall be valued at Fair Market Value on the exercise date; or
          (iii) By the optionee delivering to the Company a properly executed
exercise notice together with irrevocable instructions to a broker to promptly
deliver to the Company cash or a check payable and acceptable to the Company to
pay the purchase price; provided that in the event the optionee chooses to pay
the purchase price as so provided, the optionee and the broker shall comply with
such procedures and enter into such agreements of indemnity and other agreements
as the Committee shall prescribe as a condition of such payment procedure. The
Company need not act upon such exercise notice until the Company receives full
payment of the exercise price; or
          (iv) By any other means (including, without limitation, by delivery of
a promissory note of the optionee payable on such terms as are specified by the
Committee) which the Committee determines are consistent with the purpose of the
Plan and with applicable laws and regulations.
     The delivery of certificates representing shares of Stock to be purchased
pursuant to the exercise of a Stock Option will be contingent upon receipt from
the Optionee (or a purchaser acting in his stead in accordance with the
provisions of the Stock Option) by the Company of the full purchase price for
such shares and the fulfillment of any other requirements contained in the Stock
Option or imposed by applicable law.
     (e)  Non-transferability of Options. Except as the Committee may provide
with respect to a Non-Statutory Stock Option, no Stock Option shall be
transferable other than by will or by the laws of descent and distribution and
all Stock Options shall be exercisable, during the optionee's lifetime, only by
the optionee.
     (f)  Annual Limit on Incentive Stock Options. To the extent required for
"incentive stock option" treatment under Section 422 of the Code, the aggregate
Fair Market Value (determined as of the time of grant) of the Stock with respect
to which incentive stock options granted under this Plan and any other plan of
the Company or its Subsidiaries become exercisable for the first time by an
optionee during any calendar year shall not exceed $100,000.
     (g)  Form of Settlement. Shares of Stock issued upon exercise of a Stock
Option shall be free of all restrictions under the Plan, except as otherwise
provided in this Plan.

SECTION 6. Restricted Stock Awards.

     (a)  Nature of Restricted Stock Award. The Committee in its discretion may
grant Restricted Stock Awards to any Eligible Person, entitling the recipient to
acquire, for a purchase price determined by the Committee, shares of Stock
subject to such restrictions and conditions as the Committee may determine at
the time of grant ("Restricted Stock"), including continued employment and/or
achievement of pre-established performance goals and objectives.
     (b)  Acceptance of Award. A participant who is granted a Restricted Stock
Award shall have no rights with respect to such Award unless the participant
shall have accepted the Award within sixty (60) days (or such shorter date as
the Committee may specify) following the award date by making payment to the
Company of the specified purchase price, of the shares covered by the Award and
by executing and delivering to the Company a written instrument that sets forth
the terms and conditions applicable to the Restricted Stock in such form as the
Committee shall determine.
     (c)  Rights as a Shareholder. Upon complying with Section 6(b) above, a
participant shall have all the rights of a shareholder with respect to the

<PAGE>

Restricted Stock, including voting and dividend rights, subject to
non-transferability restrictions and Company repurchase or forfeiture rights
described in this Section 6 and subject to such other conditions contained in
the written instrument evidencing the Restricted Award. Unless the Committee
shall otherwise determine, certificates evidencing shares of Restricted Stock
shall remain in the possession of the Company until such shares are vested as
provided in Section 6(e) below.
     (d)  Restrictions. Shares of Restricted Stock may not be sold, assigned,
transferred, pledged or otherwise encumbered or disposed of except as
specifically provided herein. In the event of termination of employment by the
Company and its Subsidiaries for any reason (including death, Disability, Normal
Retirement and for Cause), the Company shall have the right, at the discretion
of the Committee, to repurchase shares of Restricted Stock with respect to which
conditions have not lapsed at their purchase price, or to require forfeiture of
such shares to the Company if acquired at no cost, from the participant or the
participant's legal representative. The Company must exercise such right of
repurchase or forfeiture within ninety (90) days following such termination of
employment (unless otherwise specified in the written instrument evidencing the
Restricted Stock Award).
     (e)  Vesting of Restricted Stock. The Committee at the time of grant shall
specify the date or dates and/or the attainment of pre-established performance
goals, objectives and other conditions on which the non-transferability of the
Restricted Stock and the Company's right of repurchase or forfeiture shall
lapse. Subsequent to such date or dates and/or the attainment of such
preestablished performance goals, objectives and other conditions, the shares on
which all restrictions have lapsed shall no longer be Restricted Stock and shall
be deemed "vested." The Committee at any time may accelerate such date or dates
and otherwise waive or, subject to Section 13, amend any conditions of the
Award.
     (f)  Waiver, Deferral and Reinvestment of Dividends. The written instrument
evidencing the Restricted Stock Award may require or permit the immediate
payment, waiver, deferral or investment of dividends paid on the Restricted
Stock.

SECTION 7. Unrestricted Stock Awards.

     (a)  Grant or Sale of Unrestricted Stock. The Committee in its discretion
may grant or sell to any Eligible Person shares of Stock free of any
restrictions under the Plan ("Unrestricted Stock") at a purchase price
determined by the Committee. Shares of Unrestricted Stock may be granted or sold
as described in the preceding sentence in respect of past services or other
valid consideration.
     (b)  Restrictions on Transfers. The right to receive unrestricted Stock may
not be sold, assigned, transferred, pledged or otherwise encumbered, other than
by will or the laws of descent and distribution.

SECTION 8. Performance Share Awards.

     (a)  Nature of Performance Shares. A Performance Share Award is an award
entitling the recipient to acquire shares of Stock upon the attainment of
specified performance goals. The Committee may make Performance Share Awards
independent of or in connection with the granting of any other Award under the
Plan. Performance Share Awards may be granted under the Plan to any Eligible
Person. The Committee in its discretion shall determine whether and to whom
Performance Share Awards shall be made, the performance goals applicable under

<PAGE>

each such Award, the periods during which performance is to be measured, and all
other limitations and conditions applicable to the awarded Performance Shares.

SECTION 9. Stock Appreciation Rights.

     The Committee in its discretion may grant Stock Appreciation Rights to any
Eligible Person (i) alone, or (ii) simultaneously with the grant of a Stock
Option and in conjunction therewith or in the alternative thereto. A Stock
Appreciation Right shall entitle the participant upon exercise thereof to
receive from the Company, upon written request to the Company at its principal
offices (the "Request"), a number of shares of Stock (with or without
restrictions as to substantial risk of forfeiture and transferability, as
determined by the Committee in its sole discretion), an amount of cash, or any
combination of Stock and cash, as specified in the Request (but subject to the
approval of the Committee in its sole discretion, at any time up to and
including the time of payment, as to the making of any cash payment), having an
aggregate Fair Market Value equal to the product of (i) the excess of Fair
Market Value, on the date of such Request, over the exercise price per share of
Stock specified in such Stock Appreciation Right or its related Option,
multiplied by (ii) the number of shares of Stock for which such Stock
Appreciation Right shall be exercised. Notwithstanding the foregoing, the
Committee may specify at the time of grant of any Stock Appreciation Right that
such Stock Appreciation Right may be exercisable solely for cash and not for
Stock.

SECTION 10. Termination of Stock Options and Stock Appreciation Rights.

     (a)  Incentive Stock Options:
          (i)  Termination by Death. If any participant's employment by the
Company and its Subsidiaries terminates by reason of death, any Incentive Stock
Option owned by such participant may thereafter be exercised to the extent
exercisable at the date of death, by the legal representative or legatee of the
participant, for a period of two (2) years (or such other period as the
Committee shall specify at any time) from the date of death, or until the
expiration of the stated term of the Incentive Stock Option, if earlier.
          (ii) Termination by Reason of Disability or Normal Retirement.
          (A)  Any Incentive Stock Option held by a participant whose employment
by the Company and its Subsidiaries has terminated by reason of Disability may
thereafter be exercised, to the extent it was exercisable at the time of such
termination, for a period of one (1) year (or such other period as the Committee
shall specify at any time) from the date of such termination of employment, or
until the expiration of the stated term of the Option, if earlier.
          (B)  Any Incentive Stock Option held by a participant whose employment
by the Company and its Subsidiaries has terminated by reason of Normal
Retirement may thereafter be exercised, to the extent it was exercisable at the
time of such termination, for a period of ninety (90) days (or such other period
as the Committee shall specify at any time) from the date of such termination of
employment, or until the expiration of the stated term of the Option, if
earlier.
          (C)  The Committee shall have sole authority and discretion to
determine whether a participant's employment has been terminated by reason of
Disability or Normal Retirement.
          (D)  Except as otherwise provided by the Committee at the time of
grant, the death of a participant during a period provided in this Section
10(a)(ii) for the exercise of an Incentive Stock Option shall extend such period

<PAGE>

for two (2) years from the date of death, subject to termination on the
expiration of the stated term of the Option, if earlier.
          (iii) Termination for Cause. If any participant's employment by the
Company and its Subsidiaries has been terminated for Cause, any Incentive Stock
Option held by such participant shall immediately terminate and be of no further
force and effect; provided, however, that the Committee may, in its sole
discretion, provide that such Option can be exercised for a period of up to
thirty (30) days from the date of termination of employment or until the
expiration of the stated term of the Option, if earlier.
          (iv) Other Termination. Unless otherwise determined by the Committee,
if a participant's employment by the Company and its Subsidiaries terminates for
any reason other than death, Disability, Normal Retirement or for Cause, any
Incentive Stock Option held by such participant may thereafter be exercised, to
the extent it was exercisable on the date of termination of employment, for
ninety (90) days (or such other period as the Committee shall specify at any
time) from the date of termination of employment or until the expiration of the
stated term of the Option, if earlier.
     (b)  Non-Statutory Stock Options and Stock Appreciation Rights. Any
Non-Statutory Stock Option or Stock Appreciation Right granted under the Plan
shall contain such terms and conditions with respect to its termination as the
Committee, in its discretion, may from time to time determine.

SECTION 11. Tax Withholding.

     (a)  Payment by Participant. Each participant shall, no later than the date
as of which the value of an Award or of any Stock or other amounts received
thereunder first becomes includable in the gross income of the participant for
Federal income tax purposes, pay to the Company, or make arrangements
satisfactory to the Committee regarding payment of any Federal, state, local
and/or payroll taxes of any kind required by law to be withheld with respect to
such income. The Company and its Subsidiaries shall, to the extent permitted by
law, have the right to deduct any such taxes from any payment of any kind
otherwise due to the participant.
     (b)  Payment in Shares. A Participant may elect, with the consent of the
Committee, to have such tax withholding obligation satisfied, in whole or in
part, by (i) authorizing the Company to withhold from shares of Stock to be
issued pursuant to an Award a number of shares with an aggregate Fair Market
Value (as of the date the withholding is effected) that would satisfy the
minimum withholding amount due with respect to such Award, or (ii) transferring
to the Company shares of Stock owned by the participant for a period of at least
six months and with an aggregate Fair Market Value (as of the date the minimum
withholding is effected) that would satisfy the withholding amount due.

SECTION 12. Transfer, Leave of Absence, Etc.

     For purposes of the Plan, the following events shall not be deemed a
termination of employment:
          (i)  a transfer to the employment of the Company from a Subsidiary or
from the Company to a Subsidiary, or from one Subsidiary to another;
          (ii) an approved leave of absence for military service or sickness, or
for any other purpose approved by the Company, if the employee's right to
re-employment is guaranteed either by a statute or by contract or under the
policy pursuant to which the leave of absence was granted or if the Committee
otherwise so provides in writing.

<PAGE>

SECTION 13. Amendments and Termination.

     The Board may at any time amend or discontinue the Plan and the Committee
may at any time amend or cancel any outstanding Award (or provide substitute
Awards at the same or reduced exercise or purchase price or with no exercise or
purchase price, but such price, if any, must satisfy the requirements which
would apply to the substitute or amended Award if it were then initially granted
under this Plan) for the purpose of satisfying changes in law or for any other
lawful purpose, but no such action shall adversely affect rights under any
outstanding Award without the holder's consent. However, no such amendment,
unless approved by the directors of the Company, shall be effective if it would
cause the Plan to fail to satisfy the incentive stock option requirements of the
Code.

SECTION 14. Status of Plan.

     With respect to the portion of any Award which has not been exercised and
any payments in cash, Stock or other consideration not received by a
participant, a participant shall have no rights greater than those of a general
creditor of the Company unless the Committee shall otherwise expressly determine
in connection with any Award or Awards. In its sole discretion, the Committee
may authorize the creation of trusts or other arrangements to meet the Company's
obligations to deliver Stock or make payments with respect to Awards hereunder,
provided that the existence of such trusts or other arrangements is consistent
with the provision of the foregoing sentence.

SECTION 15. Change of Control Provisions.

    Upon the occurrence of a Change of Control as defined in this Section 15:
          (i)  subject to the provisions of clause (iii) below, after the
effective date of such Change of Control, each holder of an outstanding Stock
Option, Restricted Stock Award, Performance Share Award or Stock Appreciation
Right shall be entitled, upon exercise of such Award, to receive, in lieu of
shares of Stock (or consideration based upon the Fair Market Value of Stock),
shares of such stock or other securities, cash or property (or consideration
based upon shares of such stock or other securities, cash or property) as the
holders of shares of Stock received in connection with the Change of Control;
          (ii) the Committee may accelerate the time for exercise of, and waive
all conditions and restrictions on, each unexercised and unexpired Stock Option,
Restricted Stock Award, Performance Share Award and Stock Appreciation Right,
effective upon a date prior or subsequent to the effective date of such Change
of Control, specified by the Committee; or
          (iii)  each outstanding Stock Option, Restricted Stock Award,
Performance Share Award and Stock Appreciation Right may be cancelled by the
Committee as of the effective date of any such Change of Control provided that
(x) notice of such cancellation shall be given to each holder of such an Award
and (y) each holder of such an Award shall have the right to exercise such Award
to the extent that the same is then exercisable or, in full, if the Committee
shall have accelerated the time for exercise of all such unexercised and
unexpired Awards, during the thirty (30) day period preceding the effective date
of such Change of Control.
     (b)  "Change of Control" shall mean the occurrence of any one of the
following events:
          (i)  any "person" (as such term is used in Sections 13(d) and 14(d)(2)
of the Act) becomes a "beneficial owner" (as such term is defined in Rule 13d-3
promulgated under the Act) (other than the Company, any trustee or other
fiduciary holding securities under an employee benefit plan of the Company, or

<PAGE>

any corporation owned, directly or indirectly, by the stockholders of the
Company in substantially the same proportions as their ownership of stock of the
Company), directly or indirectly, of securities of the Company representing
fifty percent (50%) or more of the combined voting power of the Company's then
outstanding securities; or
          (ii) the stockholders of the Company approve a merger or consolidation
of the Company with any other corporation or other entity, other than a merger
or consolidation which would result in the voting securities of the Company
outstanding immediately prior thereto continuing to represent (either by
remaining outstanding or by being converted into voting securities of the
surviving entity) more than sixty-five percent (65%) of the combined voting
power of the voting securities of the Company or such surviving entity
outstanding immediately after such merger or consolidation; or
          (iii)  the stockholders of the Company approve a plan of complete
liquidation of the Company or an agreement for the sale or disposition by the
Company of all or substantially all of the Company's assets.

SECTION 16. General Provisions.

     (a)  No Distribution; Compliance with Legal Requirements. The Committee may
require each person acquiring shares pursuant to an Award to represent to and
agree with the Company in writing that such person is acquiring the shares
without a view to distribution thereof.
     No shares of Stock shall be issued pursuant to an Award until all
applicable securities laws and other legal and stock exchange requirements have
been satisfied. The Committee may require the placing of such stop orders and
restrictive legends on certificates for Stock and Awards as it deems
appropriate.
     (b)  Delivery of Stock Certificates. Delivery of stock certificates to
participants under this Plan shall be deemed effected for all purposes when the
Company or a stock transfer agent of the Company shall have delivered such
certificates in the United States mail, addressed to the participant, at the
participant's last known address on file with the Company.
     (c)  Other Compensation Arrangements; No Employment Rights. Nothing
contained in this Plan shall prevent the Board from adopting other or additional
compensation arrangements, including trusts, subject to stockholder approval if
such approval is required; and such arrangements may be either generally
applicable or applicable only in specific cases. The adoption of the Plan or any
Award under the Plan does not confer upon any employee any right to continued
employment with the Company or any Subsidiary.

SECTION 17. Effective Date of Plan.

     The Plan shall become effective upon approval by the board of directors of
the Company; however, no Incentive Stock Option shall be granted unless and
until the Plan is ratified at a meeting of the stockholders of the Company.

SECTION 18. Governing Law.

     This Plan shall be governed by, and construed and enforced in accordance
with, the substantive laws of the State of Colorado without regard to its
principles of conflicts of laws.Exhibit 10.1

                                LICENSE AGREEMENT

         THIS LICENSE AGREEMENT ("Agreement") is entered into as of the 14th day
of January, 2002, (the "Effective Date") by and between PROFILE, LLC, a Delaware
limited liability company ("Profile") and PRO URO CARE INC., a Minnesota
corporation ("Licensee").

                                    RECITALS

         WHEREAS, Profile owns or has licensed the Licensed Technology (defined
below); and

         WHEREAS, the parties desire for Licensee to be granted an exclusive
license to the Licensed Technology in the defined field of use, subject to the
terms and conditions of this Agreement.

         NOW THEREFORE, in consideration of the foregoing and the covenants and
premises contained in this Agreement, the parties agree as follows:

                                    ARTICLE 1

                                   DEFINITIONS

         As used herein, capitalized terms will have the meanings set forth
below.

         1.1 "Affiliate" shall mean any entity that controls, is controlled by
or is under common control with a party hereto. "Control" shall mean the
possession of the power to direct or cause the direction of the management and
policies of such entity, whether through the ownership of voting securities, by
contract or otherwise. Profile represents that each of ArMed, Inc. and ArMed
L.L.C. are not an Affiliate of Profile, within the meaning of this definition.

         1.2 "Confidential Information" shall mean any confidential or
proprietary information embodied in the Devices or Licensed Technology, and any
information which relates to any research project, work in process, future
development, scientific, engineering, manufacturing, marketing, business plan,
financial or personnel matter relating to either party, its present or future
products, sales, suppliers, customers, employees, investors or business, whether
in oral, written, graphic or electronic form.

         1.3 "Devices" shall mean any composition of matter, material or product
that is either covered by the Licensed Patents or the Licensed Know-how, or
whose manufacture, use or sale would constitute, but for the license granted to
Licensee pursuant to this agreement, an infringement of any pending or issued
claim within the Licensed Patents.

         1.4 "Field of Use" shall mean the diagnosis of and the treatment of (a)
benign prostatic hyperplasia; (b) prostatitis; (c) prostate cancer; or (d) any
other conditions of or disorders of the prostate, whether healthy or diseased,
and any other condition of urologic disorder which may be diagnosed, imaged or
treated using any diagnostic or imaging process.

         1.5 "Licensed Know-how" means all techniques, inventions, practices,
methods, knowledge, skill, experience, bench testing information, and all other
information and data relating to the Licensed Patents or the Field of Use, and
which are now or in the future owned or licensed, by Profile or its Affiliates.

         1.6 "Licensed Names" means any Names as defined in Section 2.3 which
are included in the license, made hereunder pursuant to the provisions of
Section 2.3 (it being understood that there may be no such Names).

<PAGE>

         1.7 "Licensed Patents" means (a) the patents and patent applications
listed on Exhibit A hereto, (b) any future patents and patent applications
pertaining to or that have application in the Field of Use, and which are owned
or licensed, by Profile, and (c) all foreign counterparts, all substitutions,
extensions, reissues, renewals, continuations and continuations in part relating
to any Licensed Patents and their foreign counterparts, and which are owned or
licensed, by Profile or its Affiliates. Exhibit A shall be updated by the
parties as needed from time to time during the term of this Agreement.

         1.8 "Licensed Technology" means (a) the inventions, discoveries,
processes, devices and/or claims covered under the Licensed Patents; and (b) the
Licensed Know-how, and (c) the Licensed Names (if any).

         1.9 "Net Sales" means all revenues recognized in accordance with
generally accepted accounting principles relating to the sale of Devices by or
for Licensee, less transportation charges, discounts actually taken, credits
allowed for defective or returned goods, and other allowances (actually paid or
allowed, including but not limited to, prompt payment and volume discounts,
charge backs from wholesalers and other allowances granted to the end commercial
customer of the Devices, whether in cash or trade), insurance and sales and
other taxes based on sales prices when included in gross sales, but not
including taxes assessed on income derived from such sales.

                                    ARTICLE 2

                     GRANT OF LICENSE AND OTHER OBLIGATIONS

         2.1 License Grant. Subject to the terms and conditions of this
Agreement, Profile hereby grants to Licensee an exclusive, worldwide,
royalty-bearing, limited license under the Licensed Technology to make, have
made, import, use, sell and have sold the Devices solely within the Field of
Use.

         2.2 Degree of Exclusivity. Except as otherwise provided herein, the
license granted in Section 2.1 shall be exclusive for the life of the Agreement.
As used herein, "exclusive" shall mean that Profile may not grant any other
license to any other third party of the Licensed Technology, in whole or in
part, within the Field of Use, and that Profile and its Affiliates may not
practice any claim encompassed within the foregoing within the Field of Use.
Notwithstanding the foregoing, Profile and other third parties reserve the right
to make, to have made, use or sell, directly or through others, for any products
embodying or otherwise using the Licensed Technology for applications outside
the Field of Use.

         2.3 Name License. To the extent Profile owns any name, trade name,
trademark or other designation (collectively, "Names") that are used in
connection with the Licensed Technology, said Names shall be included in and
subject to the license granted in Section 2.1.

         2.4 Sublicense. Licensee may grant to third parties a sublicense to
manufacture, use, import or sell Devices, provided that a least a majority of
the members of Licensee's Board of Directors (the "Board") approves such
sublicense.

         2.5 Licensed Know-how. Profile will provide or make available all
Licensed Knowhow to Licensee in a timely manner.

                                       2
<PAGE>

                                    ARTICLE 3

                                    OWNERSHIP

         Licensee acknowledges and agrees that, as between Profile and Licensee,
Profile shall retain all rights to the Licensed Technology, and Licensee shall
have no rights in the Licensed Technology other than those rights expressly
granted to Licensee under this Agreement.

                                    ARTICLE 4

                                  CONSIDERATION

         4.1 Calculation and Payment of Royalties. Beginning on the Effective
Date, Licensee shall pay to Profile an ongoing royalty pursuant to this Section
4.1.

                  (a) Calculation of Royalties. Within thirty (30) days after
the end of each calendar quarter, Licensee shall pay to Profile a royalty at the
percentage indicated in the chart below on the Net Sales of all Devices sold or
distributed during such calendar quarter. The applicable percentage rate depends
on the level of Net Sales achieved during each calendar year, and is as follows:

                  Sales During Calendar Year             Royalty Rate
                  --------------------------             ------------

                  From $0 to $30,000,000                   3.05%

                  $30,000,001 to $100,000,000              2.05%

                  Over $100,000,000                        1.05%

                  (b) Payment of Royalties. At the same time that it makes
payments of royalties due with respect to a calendar quarter, Licensee shall
deliver to Profile a true and complete accounting of sales of Devices and
receipts from those sales during the quarter, with a separate accounting of
sales and receipts by country and a calculation of the royalty payment due
Profile for such calendar quarter. If no sales of Devices were made in such
quarter, then Licensee's statement shall be a statement to such effect. Licensee
hereby covenants that if it desires to sell, lease or otherwise place any
Devices in exchange for consideration in a manner that makes it impractical to
calculate the royalty due, it will not do so without first devising a mechanism
for the calculation of royalties thereon and obtaining Profile's prior written
consent for such mechanism.

         4.2 Foreign Payments. In transactions giving rise to an obligation to
make payment hereunder with respect to which Licensee receives payment in a
currency other than U.S. Dollars, all payments required to be made by Licensee
under Section 4.1 shall be. converted, prior to payment, into U.S. Dollars at
the applicable rate of exchange of Citibank, N.A., in New York, New York, on the
last day of the calendar quarter in which such transaction occurred. If Licensee
is prevented from making any payment under this Agreement by virtue of the laws
of the country from which the payment is to be made, Licensee may deposit the
amount that has accrued to Profile's account in the currency of such country in
a bank in such country that is acceptable to Profile.

         4.3 Overdue Payments. Payments due to Profile hereunder shall, if not
paid when due under the terms of this Agreement, bear simple interest at the
lesser of 1.5% per month or the highest rate permitted by law, calculated on the
basis of a 360-day year for the number of days actually elapsed, beginning on
the due date and ending on the day prior to the day on which payment is made in
full. Interest accruing under this Section shall be due to Profile on demand.
The accrual or receipt by Profile of interest under this Section shall not
constitute a waiver by Profile of any right it may otherwise have to declare a
default under this Agreement or to terminate this Agreement.

                                       3
<PAGE>

                                    ARTICLE 5

                                OTHER OBLIGATIONS

         5.1 Licensee Responsibility. Licensee shall direct, and shall
diligently proceed with the development, manufacture, and sale of Devices within
the Field of Use and shall earnestly and diligently endeavor to market the same
within a reasonable time after execution of this Agreement and in quantities
sufficient to meet the market demands therefor. During the time period
commencing on the Effective Date and ending on the earlier of December 31, 2002
or the date of a Qualifying Transaction, as defined in Section 7.2 below, it is
agreed that Licensee will fund development of the Licensed Technology for the
Field of Use at an average rate of not less than $25,000 per month and not in
excess of $35,000 per month. The parties acknowledge that the nature of such
development means that payments will not necessarily be incurred on a regular
monthly basis. Therefore, compliance with the requirements of this Section shall
be determined based on average monthly expenditures during six (6) month
periods, with the first such period to commence on the Effective Date, the
second such period to commence on the date six (6) months after the Effective
Date, and so on.

         5.2 Patent Protection and Prosecution. Commencing on the Effective
Date, Licensee shall be responsible for the patent prosecution and legal work
necessary to maintain the Licensed Patents for applications in the Field of Use.
In connection with these activities, the parties have the following agreements
and understandings:

                  (a) During the time period commencing on the Effective Date
and through the date of a Qualifying Transaction, all decisions about
prosecution of any patent or patent application will be made jointly by Profile
and Licensee, with the decisions to be mutually acceptable to both parties. In
this connection, it is understood that expenditures shall be determined in the
exercise of the parties' reasonable business judgment, taking into account
expected returns from the expenditures. After the date of a Qualifying
Transaction, the decisions regarding prosecution of any patents or patent
applications shall be made by the board of Licensee in the exercise of its
reasonable business judgment. Wherever the Board of Licensee makes a decision
that it will not continue to maintain a patent, Licensee shall promptly advise
Profile of this decision so that Profile may decide whether or not it wishes to
pay the maintenance fees.

                  (b) Where an expenditure is of a nature that it will provide
benefits which apply both in the Field of Use and outside the Field of Use, the
parties shall reach agreement as to how the expenditure shall be shared between
Profile and Licensee, based upon a reasonable apportionment of such expenses
between Licensee and Profile. Licensee shall not be responsible for patent
prosecution and legal work relating to the Licensed Patents outside of the Field
of Use, and Profile shall determine, in its discretion, whether it wishes to
incur such expenses.

                  (c) Exhibit B attached hereto outlines the expenditures which
are expected to be required during the next twelve (12) months. The parties have
agreed that these are the expenditures which will be made in or about this time
period.

                  (d) The Board of Licensee shall determine the nature and
extent of expenditures which will be incurred by Licensee pursuant to this
section, in the exercise of the Board's reasonable business judgment. For these
purposes, the Board shall consider and take into account the amount and timing
of expenses, and the potential benefit to Licensee, considering both possible
revenues which might be received, the risk that the revenues will not be
achieved, and the expected cost; as well as other germane factors.

                                       4
<PAGE>

                  (e) Profile represents that Exhibit C attached hereto lists,
in reasonable detail, the type and amount of expenditures made by Profile, or
its predecessors in interest, with respect to the Licensed Technology for patent
prosecution and legal work for applications in the Field of Use.

                  (f) The parties agree that Licensee shall determine the
professionals to be used for patent prosecution and activities under this
Section, subject to the consent of Profile, such consent not to be unreasonably
withheld or delayed. Without limiting Licensee's right to designate other
professionals, Profile hereby consents to the use of firm of Fish & Richardson
for these purposes.

                  (g) Licensee will keep Profile informed on a regular basis of
the status of the License Patents and the actions taken under this Section.

         5.3 Government Approvals. As between the parties, Licensee shall be
solely obligated to obtain all necessary governmental approvals for the
manufacture, use, and sale of Devices within the Field of Use in the United
States or any other countries. It is understood that decisions on what
governmental approvals should be obtained shall be made by Licensee in the
exercise of its reasonable business judgment.

         5.4 Progress Reports. Beginning at the end of the first anniversary of
the Effective Date and annually thereafter, Licensee shall submit to Profile a
summary progress report covering Licensee's activities in the preceding year
related to the development and testing of all Devices within the Field of Use
and Licensee's progress, if any, in obtaining governmental approvals necessary
for marketing such products. Such progress reports shall include, but not be
limited to, a summary of the following topics: research and development work
completed; key scientific discoveries; work in progress; current schedule of
anticipated events or milestones; and market plans for introduction of new or
additional Devices.

         5.5 Patent Marking. Licensee shall mark all Devices made, used, or sold
under the terms of this Agreement, or their containers, in accordance with 35
U.S.C. ss. 287(a) or any other successor statute in the United States and the
applicable patent marking laws of any other country. Upon Profile' written
request, Licensee shall furnish reasonable and representative samples of the
Devices to demonstrate compliance with this Section.

         5.6 Insurance. Licensee, at its sole cost and expense, shall insure its
activities in connection with the exercise of its license under this Agreement
in an appropriate amount at all times. Without limiting the foregoing, Licensee
shall obtain, keep in force, and maintain, at a minimum, Comprehensive or
Commercial Form General Liability Insurance (contractual liability included) or
an equivalent program of self-insurance with appropriate limits, which limits
will increase as needed depending on the activities of Licensee (i.e., more
coverage once human testing begins). Licensor shall be named as an additional
insured on any such policies.

                                    ARTICLE 6

                                 CONFIDENTIALITY

         6.1 Confidentiality. During the term of this Agreement and thereafter,
each party hereto will maintain in confidence all Confidential Information
disclosed by the other party hereto. Neither party will use, disclose or grant
use of such Confidential Information except as expressly authorized by this
Agreement. To the extent that disclosure is authorized by this Agreement, the
disclosing party will obtain prior agreement from its employees, agents or
consultants to whom disclosure is to be made to hold in confidence and not make
use of such information for any purpose other than those permitted by this
Agreement. Each party will use at least the same standard of care as it uses to
protect its own Confidential Information to ensure that such employees, agents
or consultants do not disclose or make any unauthorized use of such Confidential
Information. Each party will promptly notify the other upon discovery of any
unauthorized use or disclosure of the Confidential Information.

                                       5
<PAGE>

         6.2 Exceptions. The obligations of confidentiality contained in Section
6.1 will not apply to the extent that it can be established by the receiving
party by competent written proof that such Confidential Information:

                  (a) was already known to the receiving party, other than under
an obligation of confidentiality, at the time of disclosure by the other party;

                  (b) was generally available to the public or otherwise; part
of the public domain at the time of its disclosure to the other party;

                  (c) became generally available to the public or otherwise part
of the public domain after its disclosure and other than through any act or
omission of the receiving party in breach of this Agreement;

                  (d) was disclosed to the receiving party, other than under an
obligation of confidentiality, by a third party who had no obligation to the
other party not to disclose such information to others.

         The parties agree that the material financial terms of this Agreement
will also be considered Confidential Information of both parties.

         6.3 Authorized Disclosure. Each party may disclose the Confidential
Information to the extent such disclosure is reasonably necessary in complying
with applicable governmental regulations, provided that if such party is
required to make any such disclosure of the Confidential Information it will to
the extent practicable give reasonable advance notice to the other party of such
disclosure requirement so that confidential treatment of the information
required to be disclosed may be secured.

                                    ARTICLE 7

                                TERM; TERMINATION

         7.1 Term. This Agreement will commence on the Effective Date and,
unless sooner terminated as provided hereunder, will terminate upon the later of
(i) the date of the expiration of the last to expire patent included in the
Licensed Technology, or (ii) the date that the Licensee permanently ceases the
sale of Devices hereunder.

         7.2 Termination by Profile. Profile may terminate this Agreement in
accordance with the following:

                  (a) Failure to Make Timely Payment. Profile ma; y terminate
this Agreement upon ten (10) days written notice if Licensee fails to timely
make any payment to Profile required by this Agreement and fails to cure the
nonpayment within ten (10) days of written notice thereof from Licensee.

                  (b) Failure to Capitalize. Profile may terminate this
Agreement upon thirty (30) days written notice to Licensee, unless on or before
December 31, 2002 (i) Licensee has obtained equity financing in an amount which
is not less than $5,000,000, and (ii) Licensee has t least $1,500,000, which is
available and designated for the development of a diagnostic system based on the
Licensed Technology under budgets approved by the Board of Licensee. (For
purposes of this Agreement, achievement of these requirements is referred to as
a "Qualifying Transaction". In this connection, it is understood that Licensee
may obtain financing referred to in this Section, either through direct
investments by investors, or by a merger or other form of acquisition of
business combination, which results in the requisite amounts being obtained.

                                       6
<PAGE>

         Notwithstanding the foregoing, if before the expiration of the 30 day
period referred to in the notice, Licensee achieves a Qualifying Transaction
(even if it is after December 31, 2002), the termination shall not be effective,
and this License shall remain in full force and effect.

         7.3 Termination by Either Party. This Agreement may be terminated by
either party upon written notice if the other party breaches a material
provision of this Agreement, and does not cure such breach within sixty (b0)
days of written notice thereof.

         7.4 Effect of Termination.

               (a) Termination of License. Upon termination or expiration of
this Agreement for any reason, the license granted to Licensee pursuant to
~3,ection 2.1 shall automatically terminate. Licensee shall immediately cease
all use of the Licensed Technology, including all Licensed Technology included
in the Devices, and shall provide a written account to Profile of the following
within fifteen (15) days of termination:

               (1) All development in progress; sales of Devices made but not
shipped; inventory of Devices on hand as well as work in process;

               (2) Royalties due but not paid up to date of termination.

               (b) Return of Confidential Information. Within thirty (30) days
of termination of this Agreement for any reason, both parties shall return or
destroy all copies of the other party's Confidential Information and shall
provide written certification of such destruction upon request of the other
party.

               (c) Royalty Obligation. Licensee acknowledges that the
termination of this Agreement by either party for any reason shall not absolve
Licensee of its payment and other obligations under Section 4.1(b).

               (d) Survival. In the event of termination of this Agreement,
Articles 3, 4, b, 8, 9,10,11 and 12 shall survive.

               (e) Return of Stock. In the event of any termination of this
Agreement other than pursuant to clauses (i) or (ii) of Section 7.1, Profile
shall promptly return and reconvey to Licensee all shares of stock of Licensee
which have been issued to Profile, including any such shares issued pursuant to
that certain Stock Purchase Agreement, dated contemporaneously herewith between
Profile and Licensee (the "Stock Purchase Agreement"). In reconveying said
shares, Profile shall warrant that it is conveying good and marketable title
thereto, free of all liens and encumbrances, but shall make no other warranty
with respect to said shares of stock. Notwithstanding the foregoing,

                  (1) if the notice of termination is delivered after the
         "Public Company Date", as defined below, then (i) if Licensee delivers
         the notice of termination, Profile shall not be obligated to return any
         shares of stock, and (ii) if Profile delivers the notice of
         termination, Profile shall only be required to return a number of
         shares equal to fifty percent (50%) of the number of shares which,
         absent this provision, Profile would be required to return. In this
         connection, it is specifically understood that after the Public Company
         Date, where Profile is obligated to return fifty percent (50%) of the
         shares, the shares returned need not be the identical shares issued to
         Profile, but may be made up of shares which Profile has purchased or
         otherwise obtained;

                                       7
<PAGE>

                  (2) if Profile delivers written notice of termination pursuant
         to Section 7.2(a) for failure to pay royalties and if, in said notice,
         Profile provides Licensee with ninety (90) days to cure the non-payment
         rather than ten (10) days, then, if the cure is not effectuated by the
         end of the ninety (90) day period and Profile completes the
         termination, Profile will not be required to return any shares of
         stock.

         For these purposes, the "Public Company Date" shall mean the first date
on which Licensee is either a public company with shares of stock which are
publicly traded, or a direct or indirect subsidiary of a company which is a
public company with shares of stock which are publicly traded; provided,
however, that if Licensee becomes a public company through an initial public
offering, the "Public Company Date" shall be the expiration date of any lock-up
period on the shares of Profile required by the underwriters of the initial
public offering.

                                    ARTICLE 8

                         REPRESENTATIONS AND WARRANTIES

         8.1 Representations and Warranties. Each party hereby :represents and
warrants:

                  (a) Corporate Power. Such party is duly organized and validly
existing under the laws of the state of its incorporation or formation and has
full corporate or limited liability company, as applicable, power and authority
to enter into this Agreement and to carry out the provisions hereof.

                  (b) Due Authorization. Such party is duly authorized to
execute and deliver this Agreement and to perform its obligations hereunder.

                  (c) Binding Agreement. This Agreement is a legal and valid
obligation binding upon it and enforceable in accordance with its terms. The
execution, delivery and performance of this Agreement by such party does not
conflict with any agreement, instrument or understanding, oral or written, to
which it is a party or by which it may be bound, nor violate any law or
regulation of any court, governmental body or administrative or other agency
having jurisdiction over it.

         8.2 Representations and Warranties of Licensee. Licensee hereby
represents and warrants to Profile the following:

                  (a) Performance; Noninfringement. Licensee hereby represents
and warrants to Profile that it will perform its obligations hereunder in a
lawful, businesslike and professional manner and that, to the knowledge of
Licensee, the Devices do not infringe on any patent, copyright or trade secret
of a third party.

         8.3 Representations and Warranties of Profile. Profile hereby
represents and warrants to Licensee the following:

                  (a) Right to Grant License. Profile, to its knowledge, has all
rights necessary to grant the license hereunder to Licensee.

                  (b) No Infringement Claims. As of the Effective Date, to the
knowledge of Profile, the Licensed Technology does not infringe, and there are
no claims that the Licensed Technology infringes, any patent, copyright or trade
secret of a third party.

                                       8
<PAGE>

                  (c) Licensed Technology. To the knowledge of Profile, the
Licensed Technology includes all inventions, discoveries, processes, devices
and/or claims covered under patents, and all techniques, inventions, practices,
methods, knowledge, skill, experience, bench testing information, and other
information and data (collectively, "Know-how"), which Profile or its Affiliates
own or have the right to sublicense for use in the Field of 'Use. In addition,
Profile owns or has the rights to, and the Licensed Technology includes, all
inventions, discoveries, processes, devices and/or claims covered under patents,
or applications therefor, and all Knowhow and all other assets which were
previously owned by ArMed, Inc. or ArMed L.L.C. or in which ArMed, Inc. or ArMed
L.L.C. previously had an interest, which relate to the Licensed Technology.

                                    ARTICLE 9

                    INDEMNIFICATION, LIABILITY, INFRINGEMENT

         9.1 Indemnification by Licensee. Licensee hereby agrees to indemnify,
defend and hold Profile harmless from any third party suit, claim or other legal
action ("Legal Action") that alleges the Devices, or any of them, infringe any
patent, copyright, trade secret, trademark or other proprietary right, including
any reasonable costs or legal fees thereby incurred by Profile, except to the
extent Profile is required to indemnify and hold harmless Licensee pursuant to
Section 9.2, and except that this obligation shall not apply to the extent any
infringement, whether or not known, existed on the date the Licensed Technology
was licensed to Licensee hereunder. Licensee shall also indemnify, defend and
hold Profile harmless against any Legal Action resulting from or arising out of
Licensee's performance under or breach of this Agreement, including, but not
limited to, any damages, losses or liabilities, whatsoever with respect to death
or injury to any person and damage to any property arising from the design,
possession, manufacture, use, sale, support, servicing or administration of the
Devices. Profile shall give Licensee written notice of any Legal Action within
twenty (20) days of Profile's first knowledge thereof.

         9.2 Indemnification by Profile. Profile hereby agrees to indemnify,
defend and hold Licensee harmless from any Legal Action arising out of or
resulting from Profile's breach of the warranties contained in Section 8.3,
including any reasonable legal fees thereby incurred by Licensee, except to the
extent Licensee is required to indemnify Profile under Section 9.1. Licensee
shall give Profile written notice of any Legal Action within twenty (20) days of
Licensee's first knowledge thereof.

         9.3 Suit for Infringement by Others. In the event Licensee becomes
aware of any actual or threatened infringement of all or any part of the
Licensed Technology including, without limitation, the patents contained
therein, Licensee shall promptly notify Profile and Licensee shall, in its sole
discretion, determine whether to commence infringement proceedings against the
alleged third party infringer. Profile shall cooperate in such proceedings as
reasonably requested by Licensee, and at Licensee's expense. If Licensee does
not bring such action within six (6) months from date on which Licensee notified
Profile of such infringement, Profile may bring such action at its own expense.
If Profile commences infringement proceedings, Licensee shall cooperate in such
proceedings, as reasonably requested by Profile, and at Profile's expense. In
any litigation undertaken by either party against an accused infringer, neither
party shall agree to any settlement, court order or consent without the other
party's written consent to the terms thereof, which consent will not be
unreasonably withheld. The party commencing litigation against an alleged third
party infringer shall be entitled to retain any and all proceeds from such suit.

                                   ARTICLE 10

              LIMITATION OF LIABILITY AND DISCLAIMER OF WARRANTIES

         10.1 Waiver of Consequential Damages. EXCEPT FOR ANY USE OF THE
LICENSED TECHNOLOGY BY LICENSEE OUTSIDE OF THE SCOPE OF THE LICENSE GRANTED IN
SECTION 2 HEREOF, IN NO EVENT WILL EITHER PARTY BE LIABLE TO THE OTHER PARTY OR
ANY THIRD PARTY FOR ANY LOST PROFITS, LOST SAVINGS, OR OTHER INCIDENTAL,
SPECIAL, OR CONSEQUEr1TIAL DAMAGES OR FOR ANY CLAIM BY ANY OTHER PARTY, EVEN IF
SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, ARISING OUT OF
OR IN CONNECTION WITH THIS AGREEMENT, THE GRANTING OF THE LICENSE HEREUNDER, OR
THE DESIGN, MANUFACTURE, USE OR SALE OF THE LICENSED TECHNOLOGY OR DEVICES.

                                       9
<PAGE>

         10.2 Disclaimer of Warranties. EXCEPT AS EXPRESSLY PROVIDED HEREIN,
PROFILE IS PROVIDING THE LICENSED TECHNOLOGY AND ANY EQUIPMENT OR OTHER
MATERIALS PROVIDED HEREUNDER "AS IS," AND PROFILE HEREBY EXPRESSLY DISCLAIMS ANY
AND ALL WARRANTIES OF ANY KIND OR NATURE, WHETHER EXPRESS OR IMPLIED, INCLUDING,
WITHOUT LEVIITATION, THE WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A
PARTICULAR PURPOSE, RELATING TO THE LICENSED TECHNOLOGY AND ANY EQUIPMENT OR
OTHER MATERIALS PROVIDED HEREUNDER. Without limiting the generality of the
foregoing, Profile expressly does not warrant the accuracy, safety, or
usefulness for any purpose, of the Licensed Technology, any equipment or other
materials provided or made available by Profile hereunder or the Devices.
Nothing contained in this Agreement shall bi-, construed as either a warranty or
representation by Profile as to the validity or scope of any patents contained
in the Licensed Technology, and Profile assumes no liability in respect of any
infringement of any patent or other right of third parties due to the activities
of Licensee or any sublicensee under this Agreement, subject to Section 8.3(b)
above.

                                   ARTICLE 11

                                 RECORDS; AUDIT

         11.1 Records Retention. Licensee will keep complete and accurate
records pertaining to the sale of the Devices. Such records will be maintained
for a three (3) year period following the year in which any such payments were
made hereunder.

         11.2 Audit Request. Profile will have the right to engage, at, its own
expense, an independent, certified public accountant reasonably acceptable to
Licensee, to examine Licensee's records from time to time as may be necessary to
determine, with respect to any calendar year, the correctness of any report or
payment made under this Agreement. If any such audit reveals an underpayment of
more than five percent (5%) of the correct amount of royalties due hereunder,
such audit will be at the expense of Licensee. If any audit conducted on behalf
of Profile shows that Licensee underpaid the royalties due to Profile under the
licenses herein as to the period subject to the audit, then Licensee shall
immediately pay to Profile any such deficiency with interest thereon at an
annual rate equal to 2% above the U.S. dollar reference rate ("prime rate")
charged from time to time by Citibank, N.A. from the date due until paid or at
such lower rate as shall be the maximum rate permitted by law.

         11.3 Survival. This Article 11 will survive any termination of this
Agreement for a period of three (3) years.

                                   ARTICLE 12

                            MISCELLANEOUS PROVISIONS

         12.1 Entire Agreement. This Agreement (including the Exhibits,
schedules and other documents referred to herein), the Stock Purchase Agreement
and the emended and Restated Shareholder Control and Share Transfer Agreement,
dated contemporaneously herewith, by and among Profile, Licensee, Clinical
Network, Inc., Clinical Network, LLC and CS Medical Technologies, LLC contain
the entire understanding between the parties with respect to the subject matter
hereof and supersedes any prior understandings, agreements or representations,
written or oral, relating to the subject matter hereof.

                                       10
<PAGE>

         12.2 Counterparts. This Agreement may be executed in separate
counterparts, each of which will be an original and all of which taken together
shall constitute one and the same agreement, and any party hereto may execute
this Agreement by signing any such counterpart.

         12.3 Severability. Whenever possible, each provision of the Agreement
will be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of the Agreement is held to be invalid, illegal or
unenforceable under any applicable law or rule, the validity, legality and
enforceability of the other provision of this Agreement will not be affected or
impaired thereby.

         12.4 Successors and Assigns. This Agreement shall be binding upon and
inure to the benefit of the parties hereto and their respective heirs, personal
representatives and, to the extent permitted hereunder, successors and assigns.

         12.5 Assignability. Neither this Agreement nor any right, remedy,
obligation or liability arising hereunder or by reason hereof shall be
assignable (including by operation of law) by Licensee without the prior consent
of at least a majority of the members of Licensee's Board of Directors. Any
assignment which is not in accordance with this Section will be void.

         12.6 Modification, Amendment, Waiver or Termination. No provision of
the Agreement may be modified, amended waived or terminated except by an
instrument in writing signed by the parties to this agreement. No course of
dealing between the parties will modify, amend, waive or terminate any provision
of this Agreement or any rights or obligations of any party under or by reason
of this Agreement.

         12.7 Notices. All notices, consents, requests, instructions, approvals
or other communications provided for herein shall be in writing and delivered by
personal delivery, overnight courier, mail, electronic facsimile or e-mail
addressed to the receiving party at the address set forth herein. All such
communications shall be effective when received.

If to PROFILE:

                  Stan Graves
                  Graco Resources
                  2870 Old Rocky Ridge Road
                  Birmingham, AL 35243

With a copy to:

                  Peter C. Quittmeyer
                  Sutherland Asbill & Brennan LLP
                  999 Peachtree Street
                  Atlanta, GA 30309

                                       11
<PAGE>

If to Licensee, addressed to:

                  David Koenig
                  Solar Plastics, Inc.
                  732 30th Avenue S.E.
                  Minneapolis, MN 55414

With a copy to:

                  John Brower

                  Gray Plant Mooty Mooty & Bennett P.A.
                  33 South Sixth Street, Suite 3400
                  Minneapolis, MN 55402

Any party may change the address set forth above by notice to each other party
given as provided herein.

         12.8 Headings. The headings contained in this Agreement acre for
reference purposes only and shall not in any way affect the meaning or
interpretation of this Agreement.

         12.9 Governing Law. This Agreement is made in accordance with and shall
be governed and construed in accordance with the laws of the State of Minnesota,
without regard to conflicts of laws rules.

         12.10 Third-Party Benefit. Nothing in this Agreement, express or
implied, is intended to confer upon any other person any rights, remedies,
obligations or liabilities of any nature whatsoever.

         12.11 Jurisdiction and Venue. This Agreement may be enforced in any
federal court or state court sitting in Ramsey or Hennepin counties, Minnesota,
and each party consents to the jurisdiction and venue of any such court and
waives any argument that: venue in such forum is not convenient. If any party
commences any action under any tort or contract theory arising directly or
indirectly from the relationship created by this Agreement in another
jurisdiction or venue, any other party to this Agreement shall have the option
of transferring the case to the above-described venue or jurisdiction or, if
such transfer cannot be accomplished, to have such case dismissed without
prejudice.

         12.12 Waiver of Jury Trial. Each party irrevocably waives any and all
right to trial by jury in any legal proceeding arising out of or relating to
this agreement or the transactions contemplated hereby.

         12.13 Remedies. The parties agree that money damages may not be an
adequate remedy for any breach of the provisions of this Agreement and that any
party may, in its discretion, apply to any court of law or equity of competent
jurisdiction for specific performance and injunctive relief in order to enforce
or prevent any violations this Agreement, any party against whom such proceeding
is brought hereby waives the claim or defense that such party has an adequate
remedy at law and agrees not to raise the defense that the other party has an
adequate remedy at law.

         12.14 Expenses. Except as otherwise expressly provided for herein, each
party will pay its own expenses (including attorneys' and accountants' fees) in
connection with the negotiation of this Agreement, the performance of its
respective obligations hereunder and the consummation of the transactions
contemplated by this Agreement (whether consummated or not).

         12.15 Advice of Counsel. Each party acknowledges that it has been
advised by counsel in the negotiation, execution and delivery of this Agreement.

                                       12
<PAGE>

         12.16 Relationship of the Parties. Neither party is, nor will be deemed
to be, an agent or legal representative of the other party for any purpose.
Neither party will be entitled to enter into any contracts in the name of or on
behalf of the other party, and neither party will be entitled to pledge the
credit of the other party in any way or hold itself out as having authority to
do so. Except as provided in Section 5.7 hereof with respect to the Accepted
Debt of ArMed, no party will incur any debts or make any commitments for the
other.

         12.17 Force Majeure. Neither party will be liable to the other for loss
or damages or will have any right to terminate this Agreement for any default or
delay (except any default or delay in the payment of money due hereunder)
attributable to any fire, floods, earthquake, embargo, war, act of war (whether
declared or not), insurrections, riots,, civil commotions, strikes, lockouts or
other labor disturbances, acts of God or act, omission or delay in acting by any
governmental authority or the other party, if the party affected will give
prompt notice of any such cause to the other party. The party giving such notice
will thereupon be excused from such of its obligations hereunder as it is
thereby disabled from performing for so long as it is so disabled and for thirty
(30) days thereafter; provided, however, that such affected party commences and
continues to take reasonable and diligent actions to cure such cause.

         12.18 Export Control. Licensee acknowledges that the Licensed
Technology and .Devices may be subject to the export control laws and
regulations of the United States of America and it hereby agrees to obey any and
all such laws and regulations. Licensee agrees not to take any actions that
would cause either party to violate the U.S. Foreign Corrupt Practices Act of
1977, as amended.

         IN WITNESS WHEREOF, the parties hereto have duly executed this
Agreement, including the Exhibits attached hereto and incorporated herein by
reference.

PRO URO CARE INC.                           PROFILE, LLC

By:      [signature illegible]              By:      [signature illegible]

Title:   President                          Title:   Manager

                                       13
<PAGE>

                      FIRST AMENDMENT TO LICENSE AGREEMENT

         This Amendment to License Agreement is entered into as of this 22 day
of March, 2002, by and between Profile, L.L.C., a Delaware limited liability
company ("Profile") and Pro Uro Care Inc., a Minnesota corporation ("Licensee").

                                    Recitals:

         A. The parties entered into a License Agreement effective January 14,
2002 ("License Agreement"); and

         B. The parties desire to amend the License Agreement.

         NOW, THEREFORE, in consideration of the foregoing and the covenants and
premises contained in this Agreement, the parties agree as follows:

         1. Subsection 7.2(b) is hereby eliminated in its entirety and shall
have no further force or effect.

         2. Except as amended hereby, the License Agreement shall remain in full
force and effect and binding upon and enforceable against the parties thereto.

         IN WITNESS WHEREOF, the parties hereto have duly executed this
Agreement on the date first above referenced.

                                      PRO URO CARE INC.

                                      By: /s/ Michael Grossman
                                      Its: President

                                      PROFILE, L.L.C.

                                      By: [signature illegible]
                                      Its: Manager

<PAGE>
                                   EXHIBIT A

                            LIST OF LICENSED PATENTS

                                     PROFILE
                         SUMMARY OF PATENTS/APPLICATIONS

<TABLE>
<CAPTION>
  Patent or Application
         No                                          Title                              Status
-----------------------------------------------------------------------------------------------------
<S>                           <C>                                                   <C>
  U.S. 5,860,934              Method and Device for Mechanical Imaging of Breast    Issued 01/19/99
  (CIP of App 07/994,109)
-----------------------------------------------------------------------------------------------------
  EP 97905986.2               Method and Device for Mechanical Imaging of Breast    Filed 08/31/98
-----------------------------------------------------------------------------------------------------
  Japan 09-530984             Method and Device for Mechanical Imaging of Breast    Filed 08/27/98
-----------------------------------------------------------------------------------------------------
  U.S. 5,833,633              Device for Breast Haptic Examination Filed 11/03/97   CIP of 5,524,636)
                                                                                    Issued 11/10/98
-----------------------------------------------------------------------------------------------------
  U.S. 5,785,633              Method and Device for Mechanical Imaging of Prostate  Filed 02/27/96
   CIP of 5,524,636)                                                                Issued 07/28/98
-----------------------------------------------------------------------------------------------------
  EP 97907654.4               Method and Device for Mechanical Imaging of Prostate  Filed 09/10/98
-----------------------------------------------------------------------------------------------------
  JP 09-530983                Method and Device for Mechanical Imaging of Prostate  Filed 08/27/98
-----------------------------------------------------------------------------------------------------
  U.S. 5,836,894              Apparatus FOR MEASURING MECHANICAL PARAMETERS of the  Filed 06/10/97
   (CIP of 5,524,636)         PROSTATE AND FOR IMAGING THE PROSTATE Using such      Issued 11/17/98
                              Parameters
-----------------------------------------------------------------------------------------------------
  U.S. 5,922,018              Method for USING A TRANSRECTAL PROBE TO MECHANICALLY  Filed 06/10/97
   CIP of 5,524 636           Image the Prostate Gland                              Issued 07/13/99
-----------------------------------------------------------------------------------------------------
  U.S. 5,524,636              Method and Apparatus for ELASTICITY IMAGING           Filed 12/21/92
                                                                                    Issued 06/11/96
-----------------------------------------------------------------------------------------------------
  U.S. 5,265,612              Intracavity Ultrasonic Device for Elasticity Imaging  Filed 12/21/92
                                                                                    Issued 11/30/93
-----------------------------------------------------------------------------------------------------
  U.S. 6,142,959              Device for Palpation and Mechanical Imaging of the    Filed 07/22/99
                              Prostate                                              Issued 11/07/00
-----------------------------------------------------------------------------------------------------
  PCT/US00/19756              Device for Palpation and Mechanical Imaging of the    Filed 07/21/00
                              Prostate
-----------------------------------------------------------------------------------------------------
  U.S. 09/843,056             Apparatus and Method for Mechanical
                              IMAGING OF BREAST                                     Filed 04/26/01
-----------------------------------------------------------------------------------------------------
  PCT/US01/13551              Apparatus  AND  METHOD  FOR  MECHANICAL  IMAGING  OF  Filed 4/26/01
                              BREAST
-----------------------------------------------------------------------------------------------------
  U.S. 60/200 433             Apparatus  AND  METHOD  FOR  MECHANICAL  IMAGING  OF  Filed 4/28/00
                              BREAST
-----------------------------------------------------------------------------------------------------
  U.S. 09/819,419             Real Time Mechanical Imaging of the Prostate          Filed 03/28/01
-----------------------------------------------------------------------------------------------------
</TABLE>

<PAGE>

                                    EXHIBIT B

                       REQUIRED PATENT EXPENDITURES DURING
                                 NEXT 12 MONTHS

      Attached hereto is a copy of a letter from the law firm of Mathews,
Collins, Shepherd & Gould detailing expected costs on existing patents and
patent applications. For purposes of this exhibit, it is understood that only
expenditures shown in said letter, which are required in the next 12 months,
constitutes part of the exhibit.

      In addition, attached to the letter is a schedule showing filing costs and
prosecution costs and maintenance fees in various countries for patents. The
parties have agreed that during the next 12 months, the only countries in which
filings will be made are the European Patent Office and in Japan. These filings
will be made only for patent file number 4774-106WO, Device for Palpation and
Mechanical Imaging of the Prostate, and for file number 4774-107WO, Apparatus
and Method for Mechanical Imaging of Breasts.

      In the case of all expenditures referenced on this Exhibit B, it is
specifically understood that the provisions of Section S.2(b) apply in any case
where the expenditure is of a nature that it will provide benefits which apply
both in the Field of Use and outside the Field of Use.

<PAGE>

                                                  November 2, 2001

Via E-Mail
Mr. Todd E. Leonard
President & C.0.0.
ArMed L.L.C.
10201 Wayzata Boulevard, Ste.150
Minneapolis, Minnesota 55305

         RE:      Status Report of ArMed LLC Patent Files
                  Our Ref.: 4774-101 US
                  =====================================================

Dear Todd:

      In accordance with your request, the following lists the status and cost
estimates of your patent matters.

<TABLE>
<CAPTION>
PROSTATE
File No.          Title                              Status                                    Cost Estimate
--------          -----                              ------                                    -------------

<C>             <C>                                  <C>                                         <C>
4774-103US      Method and Device for                U.S. Patent No. 5,785,663
                Mechanical Imaging of                Issued July 28, 1998
                Prostate
                                                     Maintenance Fees Due:
                                                     January 28, 2002 (3.5 years)                $ 440.00
                                                     January 28, 2006 (7.5 years)                $1010.00
                                                     January 28, 2010 (11.5 years)               $1550.00
4774-103EP      Method and Device for                Filed September 10, 1998
                Imaging the Prostate                 Annual Fee due February 28, 2002            $ 900.38
                                                     Possible Examination by
                                                     Examiner and Related Costs                  $1500-$4000
4774-103JP      Method and Device for                Filed August 27, 1998

                Imaging the Prostate                 Request for Examination to be filed         $1830.00
                                                     by February 18, 2004
4774-103.1      Apparatus for Measuring              U.S. Patent No. 5,836,894
                Mechanical Parameters of             Issued November 17, 1998
                the Prostate and for                 Maintenance Fees Due:
                Imaging the Prostate                 May 17, 2002 (3.5 years)                    $ 440.00
                Using Such Parameters                May 17, 2006 (7.5 years)                    $1010.00
                                                     May 17, 2010 (11.5 years)                   $1550.00
</TABLE>

<PAGE>

<TABLE>
<CAPTION>
 File No.                      Title                  Status                                      Cost Estimate
 --------                      -----                  ------                                      -------------
<S>              <C>                                  <C>                                         <C>
 4774-103.2      Method for Using a                   U.S. Patent No. 5,922,018
                 Transrectal Probe to                 Issued July 13, 1999
                 Mechanically Image the
                 Prostate Gland                       Maintenance Fees Due
                                                      January 13, 2003 (3.5 years)                $ 440.00
                                                      January 13, 2007 (7.5 years)                $1010.00
                                                      January 13, 2011 (11.5 years)               $1550.00

 4774-106US      Device for Palpation                 U.S. Patent No. 6,142,959
                 and Mechanical Imaging               Issued November 7, 2000
                 of the Prostate
                                                      Maintenance Fees Due
                                                      May 7, 2004 (3.5 years)                     $ 440.00
                                                      May 7, 2008 (7.5 years)                     $1010.00
                                                      May 7, 2012 (11.5 years)                    $1550.00

 4774-106WO      Device for Palpation                 National Stage Filing                       Costs depend on
                 and Mechanical Imaging               Due January 22, 2002                        countries designated
                 of the Prostate                      Need Instructions by                        for National Stage
                                                      December 22, 2001                           filing (See attached chart)

 4774-108US        Real Time Mechanical               Filed March 28, 2001
                   Imaging of the Prostate            Pending
                                                      PCT Application Due                               $3500-$4500
                                                      March 28, 2002
                                                      Possible Examination by                           $1000-$3500
                                                      Examiner and Related Issue Fees
</TABLE>

<PAGE>

BREAST

<TABLE>
<CAPTION>
 FILE NO.           TITLE                              STATUS                                      COST ESTIMATE
 --------           -----                              ------                                      -------------
<S>                 <C>                                <C>                                         <C>
                    Method and Device for
 4774-102US         Mechanical Imaging of              U.S. Patent No. 5,860,934
                    Breast                             Issued January 19, 1999
                                                       Maintenance Fees Due:
                                                       July 19, 2002 (3.5 years)                   $ 440.00
                                                       July 19, 2006 (7.5 years)                   $1010.00
                                                       July 19, 2010 (11.5 years)                  $1550.00

 4774-102.1         Device for Breast Haptic           U.S. Patent No. 5,833,633
                    Examination                        Issued November 10, 1998
                                                       Maintenance Fees Due:
                                                       May 10, 2002 (3.5 years)                    $ 440.00
                                                       May 10, 2006 (7.5 years)                    $1010.00
                                                       May 10, 2010 (11.5 years)                   $1550.00

 4774-102EP         Method and Device for              Filed August 31, 1998
                    Mechanical Imaging of              Annual Fee due February 18, 2002            $900.38
                                                       Possible Examination by
                                                       Examiner and Related Costs                  $1500-$4000

 4774-102JP         Method and Device for              Filed August 27, 1998
                    Mechanical Imaging of              Request for Examination must be             $1830.00
                    Breast                             filed by February 18, 2004

 4774-1 07US        Apparatus and Method               Filed April 26, 2001
                    for Mechanical Imaging             Pending
                    of Breast
                                                       Possible Examination by                     $1000-$3500
                                                       Examiner and Related Issue Fees

 4774-107WO        Apparatus and Method                Filed April 26, 2001                        Costs depend on
                   for Mechanical Imaging              Pending                                     countries designated for
                   of Breast                           Demand Filed                                National Stage filing
                                                       National Phase Filing Due                   (See attached chart)
                                                       October 28, 2002 - Need
                                                       Instructions by September 28, 2002
</TABLE>

<PAGE>

MISCELLANEOUS

<TABLE>
<CAPTION>
 File N .          Title                               STATUS                                      Cost Estimate
 --------          -----                               ------                                      -------------
<S>                <C>                                 <C>
 4774-104          Method and Apparatus                U.S. Patent No. 5,524,636
                   for Elasticity Imaging              Issued June 11, 1996
                                                       Maintenance Fees Due:
                                                       December 11, 2003 (7.5 years)               $1010.00
                                                       December 11, 2007 (11.5 years)              $1550.00

 4774-105          Intracavity Ultrasonic              U.S. Patent No. 5,265,612
                   Device for Elasticity               Issued November 30, 1993
                   Imaging
                                                       Maintenance Fees Due:
                                                       May 30, 2001 (7.5 years)                    $1010.00
                                                       May 30, 2005 (11.5 years)                   $1550.00
</TABLE>

      If you have any questions, or require further assistance, please let us
know.

                                        Very truly yours,

                                        MATHEWS, COLLINS, SHEPHERD & GOULD

                                        Diane Dunn McKay

DDMIev Attachment

<PAGE>

<TABLE>
<CAPTION>
-------------------------------------------------------------------------------------------------------------------------
                                                                                           Annuities or
                                                                                           Maintenance Fees
  Countries                                                                                Over the Lifetime of
                                Filing Costs                  Prosecution                  the Patent
-------------------------------------------------------------------------------------------------------------------------
<S>                             <C>                           <C>                          <C>
  European Patent               10,000                                                     85,000
  Office*                                                     31,000**
-------------------------------------------------------------------------------------------------------------------------
  Australia                     2,500                         3,500                        10,000
-------------------------------------------------------------------------------------------------------------------------
  Brazil                        5,000                         5,000                        10,000
-------------------------------------------------------------------------------------------------------------------------
  Canada                        1,500                         2,000                        6,500
-------------------------------------------------------------------------------------------------------------------------
  China                         4,000                         3,500                        8,500
-------------------------------------------------------------------------------------------------------------------------
  Czech Republic                3,000                         3,000                        8,000
-------------------------------------------------------------------------------------------------------------------------
  Finland                       7,000                         3,000                        13,000
-------------------------------------------------------------------------------------------------------------------------
  Hon Kong                      3,000                         3,000                        9,000
-------------------------------------------------------------------------------------------------------------------------
  Hunk                          3,000                         3,000                        14,000
-------------------------------------------------------------------------------------------------------------------------
  Japan                         8,000                         3,000                        41,000***
-------------------------------------------------------------------------------------------------------------------------
  South Korea                   7,000                         3,500                        47,000***
-------------------------------------------------------------------------------------------------------------------------
  Mexico                        5,000                         3,500                        8,000
-------------------------------------------------------------------------------------------------------------------------
  Norway                        5,000
-------------------------------------------------------------------------------------------------------------------------
  New Zealand                   1,500                         2,500                        6,000
-------------------------------------------------------------------------------------------------------------------------
  Poland                        5,000                         3,000                        8,000
-------------------------------------------------------------------------------------------------------------------------
  Russian Federation            4,000                         3,500                        6,000
-------------------------------------------------------------------------------------------------------------------------
  Slovak Republic               2,500                         3,000                        8,000
-------------------------------------------------------------------------------------------------------------------------
  Turkey                        4,000
-------------------------------------------------------------------------------------------------------------------------
  Ukraine                       5,000                         3,000                        8,000
-------------------------------------------------------------------------------------------------------------------------
</TABLE>

*indicated 17 designations of Austria; Belgium; Switzerland and Liechtenstein;
Germany; Denmark; Spain; France; United Kingdom; Greece; Ireland; Italy;
Luxembourg; Monaco; Netherlands; Portugal; and Sweden.

**includes the payment of grant fees in 17 designated countries

***Note: over half of the maintenance fees for these countries occur after the
15th year of the grant of the patent

<PAGE>

                                    EXHIBIT C

                            PAST PATENT EXPECTATIONS

Past Payments to Mathews, Collins, Shepherd & Gould:

YEAR              AMOUNT
----              ------

1999              $17,28
2000              $20,823
2001              $32,421

Payments to Artann Laboratories for Patent Drafting of various Applications:
$25,000 total

TOTAL PAYMENTS FOR PATENTS: $95,533

**Note that prior to 1999, Artann Laboratories paid all patent expenses directly
to the firm of Mathews, Collins, Shepherd & Gould. No disclosure of such amounts
were made to Profile.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00065-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00065-of-00352.parquet"}]]